PI3K
Sep 15, 2026
TAGRISSO Delivers Landmark Eight-Year Survival Outcomes in Early-Stage EGFR-Mutated Lung Cancer; Scholar Rock Receives FDA Approval for ISEMBYLD; Pharming’s Joenja Receives FDA Approval as First U.S. Treatment for Children With APDS; AbbVie Reports Positive Phase 3 Results for Atogepant in Menstrual Migraine; Rezera’s Ruvonoflast Delivers Positive Inflammation Results with Favorable Safety in RESOLVE-1
TAGRISSO Demonstrates Eight-Year Landmark Survival Benefit for Patients with Early-Stage EGFR-Mutated Lung Cancer Updated exploratory findings from the Phase III ADAURA trial demonstrated that AstraZeneca’s Tagrisso (osimertinib) continued to provide a sustained and clinically meaningful overall survival (OS) be...
Read More...
Nov 17, 2016
Phosphoinositide 3-Kinase (PI3k) Inhibitors: Emerging target therapies against Cancer
Phosphoinositide 3-kinases (PI3Ks) were discovered in 1980, and since then drug developers have accelerated their research funds in order to find potential drug candidate for inhibiting PI3Ks for the treatment of cancers. Phosphatidylinositol 3-kinases (PI3Ks) are lipid kinases that act as intermediate signaling mol...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
